+ Site Statistics
References:
52,654,530
Abstracts:
29,560,856
PMIDs:
28,072,755
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn

+ Translate
+ Recently Requested

Multicenter phase-III trial of adjuvant autologous tumor cell-lysate vaccine versus no adjuvant treatment in patients with non-metastasized renal cell carcinoma after radical nephrectomy A 3-year analysis



Multicenter phase-III trial of adjuvant autologous tumor cell-lysate vaccine versus no adjuvant treatment in patients with non-metastasized renal cell carcinoma after radical nephrectomy A 3-year analysis



Journal of Urology 167(4 Supplement): 166-167




(PDF emailed within 1 workday: $29.90)

Accession: 035349876

Download citation: RISBibTeXText


Related references

Adjuvant autologous tumour cell-lysate vaccine versus no adjuvant treatment in patients with M0 renal cell carcinoma after radical nephrectomy: 3-year interim analysis of a German multicentre phase-III trial. Folia Biologica 49(2): 69-73, 2003

Multicenter randomised phase-III trial to compare tumour nephrectomy plus adjuvant autologous tumour cell-lysate vaccine versus tumour nephrectomy without adjuvant treatment for renal cell carcinoma pT2-3bpNO-3M0. European Urology Supplements 2(1): 99, 2003

An adjuvant autologous renal tumor cell vaccine reduces the risk of progression in patients with renal cell carcinoma following radical nephrectomy Final results of a multicenter phase-III trial. Journal of Urology 171(4 Supplement): 435, 2004

Adjuvant therapy of renal cell carcinoma patients with an autologous tumor cell lysate vaccine: a 5-year follow-up analysis. Anticancer Research 23(2a): 969-974, 2003

Adjuvant therapy of renal cell carcinoma patients with an autologous tumor cell lysate vaccine A 5-year follow-up analysis. Anticancer Research 22(1B): 515, January-February, 2002

Adjuvant therapy of renal cell carcinoma patients with a pure cell-lysate autologous tumor vaccine A 5-year follow-up analysis. Journal of Urology 165(5 Supplement): 187, 2001

Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial. Lancet 363(9409): 594-599, 2004

Adjuvant therapy of renal cell carcinoma with a pure-cell-lysate autologous tumor vaccine A 3-year-follow-up analysis. Proceedings of the American Association for Cancer Research Annual Meeting 39: 367, 1998

An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial. Lancet 372(9633): 145-154, 2008

Adjuvant therapy of renal cell carcinoma with a pure cell-lysate autologous tumor vaccine. Proceedings of the American Association for Cancer Research Annual Meeting 38(0): 396, 1997

Urgent patient admission to Working Group for Urological Oncology (AUO) studies on metastasized renal cell carcinoma needed: prospective randomized multicenter phase II study on resection of pulmonary metastases in clear cell renal cell carcinoma ± adjuvant sunitinib therapy over 1 year (SMAT - AN 20/04 of the AUO). Der Urologe. Ausg. a 51(2): 252-253, 2012

AUO (Working Group on Urological Oncology) study of metastasized renal cell carcinoma: prospective randomized multicenter phase II study on resection of pulmonary metastases in clear cell renal cell carcinoma with or without adjuvant sunitinib therapy over 1 year (SMAT - AN 20/04 AUO). Der Urologe. Ausg. a 50(1): 83-84, 2011

Ten-year survival analysis for renal carcinoma patients treated with an autologous tumour lysate vaccine in an adjuvant setting. Cancer Immunology, ImmunoTherapy 59(5): 687-695, 2010

Adjuvant vaccination in patients with renal cell carcinoma following radical nephrectomy is effective Final results of a multicentre phase-III Trial. European Urology Supplements 3(2): 110, 2004

Adjuvant AUO study of renal cell carcinoma after nephrectomy: randomized, double-blind, placebo-controlled phase III study (PROTECT - AN 30/10) to investigate the effectiveness and safety of pazopanib as adjuvant therapy in patients with localized or local advanced renal cell carcinoma after nephrectomy. Der Urologe. Ausg. a 50(4): 489-492, 2011